Cytokine Storm Syndromes: When Rheumatology Meets Critical Care

A Comprehensive Review for the Critical Care Physician

Dr Neeraj Manikath , Claude.ai

Abstract

Cytokine storm syndromes represent a spectrum of life-threatening hyperinflammatory conditions characterized by excessive immune activation and multiorgan dysfunction. These syndromes, including hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and severe COVID-19, present diagnostic and therapeutic challenges at the intersection of rheumatology and critical care medicine. Early recognition and prompt immunosuppressive therapy can be life-saving, yet distinguishing these conditions from sepsis remains challenging. This review provides a practical approach to diagnosis, differential diagnosis, and management of cytokine storm syndromes in the critically ill patient.

Keywords: Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome, COVID-19, sepsis, immunosuppression

Introduction

The term "cytokine storm" has gained prominence in recent years, particularly following the COVID-19 pandemic. However, this phenomenon represents a final common pathway of various hyperinflammatory conditions that critical care physicians encounter regularly. Understanding the nuances between different cytokine storm syndromes, their triggers, and appropriate therapeutic interventions is crucial for improving patient outcomes in the intensive care unit (ICU).

Cytokine storm syndromes encompass a spectrum of conditions characterized by dysregulated immune responses leading to excessive production of pro-inflammatory cytokines, particularly interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ). This hyperinflammatory state results in widespread tissue damage, coagulopathy, and multiorgan failure.

Classification and Pathophysiology

Primary Hemophagocytic Lymphohistiocytosis (HLH)

Primary HLH results from genetic defects affecting cytotoxic lymphocyte function, most commonly involving perforin (PRF1), syntaxin 11 (STX11), or Munc13-4 (UNC13D) genes. These defects prevent effective termination of immune responses, leading to uncontrolled T-cell and macrophage activation.

Pearl: Primary HLH typically presents in infancy or early childhood, but late-onset presentations can occur. Always consider genetic testing in young adults with unexplained hyperinflammatory syndromes.

Secondary HLH

Secondary HLH occurs in the setting of infections, malignancies, or autoimmune diseases. Epstein-Barr virus (EBV) is the most common infectious trigger, but bacterial, fungal, and parasitic infections can also precipitate HLH.

Hack: The "EBV rule" - In any patient with unexplained fever, cytopenias, and hepatosplenomegaly, check EBV serology and PCR. EBV-HLH has a mortality rate exceeding 50% without prompt treatment.

Macrophage Activation Syndrome (MAS)

MAS represents a form of secondary HLH occurring in patients with rheumatic diseases, particularly systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease. The pathophysiology involves excessive activation of well-differentiated macrophages rather than the defective cytotoxic function seen in primary HLH.

COVID-19-Associated Cytokine Storm

SARS-CoV-2 infection can trigger a hyperinflammatory response characterized by elevated IL-6, ferritin, and D-dimer levels, resembling other cytokine storm syndromes but with distinct clinical features including prominent pulmonary involvement and thrombotic complications.

Clinical Presentation and Diagnostic Criteria

HLH-2004 Criteria

The diagnosis of HLH requires either:

A molecular diagnosis consistent with HLH, OR
Five of the following eight criteria:
- Fever ≥38.5°C
- Splenomegaly
- Cytopenias (≥2 cell lines): Hemoglobin <90 g/L, platelets <100×10⁹/L, neutrophils <1.0×10⁹/L
- Hypertriglyceridemia (≥3.0 mmol/L) and/or hypofibrinogenemia (<1.5 g/L)
- Hemophagocytosis in bone marrow, spleen, or lymph nodes
- Low or absent NK cell activity
- Ferritin ≥500 μg/L
- Soluble CD25 (sIL-2R) ≥2,400 U/mL

Oyster: The HLH-2004 criteria were designed for pediatric patients and may be too restrictive for adults. Many experts advocate for a lower threshold in critically ill adults.

H-Score for Adults

The H-Score provides a probability-based approach for diagnosing HLH in adults:

Known immunosuppression: +18 points
Temperature >38.4°C: +33 points
Organomegaly: +23 points (hepatomegaly), +16 points (splenomegaly)
Cytopenias: Variable points based on severity
Ferritin levels: +35 points (>2,000 ng/mL), +50 points (>6,000 ng/mL)
Triglycerides >1.59 mmol/L: +44 points
Fibrinogen <2.5 g/L: +30 points
AST >30 U/L: +19 points
Hemophagocytosis on bone marrow aspirate: +35 points

H-Score interpretation:

<90: <1% probability of HLH
90-169: 1-87% probability
170-249: 88-93% probability
≥250: >99% probability

Pearl: An H-Score ≥169 in the appropriate clinical context should prompt consideration of HLH-directed therapy while awaiting confirmatory tests.

Differential Diagnosis: The Great Mimicker

Sepsis vs. Cytokine Storm Syndromes

Distinguishing cytokine storm syndromes from sepsis represents one of the greatest challenges in critical care medicine. Both conditions present with fever, multiorgan dysfunction, and elevated inflammatory markers.

Key Differentiating Features:

Favoring Cytokine Storm Syndromes:

Extremely high ferritin (>3,000 ng/mL, often >10,000 ng/mL)
Significant cytopenias (particularly thrombocytopenia and neutropenia)
Hepatosplenomegaly
Markedly elevated triglycerides
Low fibrinogen (consumptive, not synthetic failure)
Hemophagocytosis on bone marrow examination

Favoring Sepsis:

Positive cultures or clear infectious source
Neutrophilia (early) or left shift
Elevated lactate
Typical sepsis biomarkers (procalcitonin, CRP in expected ranges)
Response to antimicrobials

Hack - The "Ferritin Rule": In critically ill patients with unexplained multiorgan dysfunction, a ferritin >3,000 ng/mL should trigger evaluation for cytokine storm syndromes. Ferritin >10,000 ng/mL is highly suggestive of HLH.

Oyster: Infection can trigger HLH, and HLH predisposes to secondary infections. These conditions can coexist, making diagnosis and management particularly challenging.

Laboratory Investigations

Essential Tests for Diagnosis

Complete Blood Count with Differential
- Look for progressive cytopenias
- Examine peripheral smear for hemophagocytes
Biochemical Markers
- Ferritin (serial measurements)
- Triglycerides and fibrinogen
- LDH, AST, bilirubin
- Albumin
Immunological Studies
- Soluble IL-2 receptor (sCD25)
- NK cell activity (specialized centers)
- Flow cytometry for perforin expression
Bone Marrow Examination
- Essential for demonstrating hemophagocytosis
- Exclude hematological malignancy

Pearl: Hemophagocytosis may be absent early in the disease course. Repeat bone marrow examination if clinical suspicion remains high.

Advanced Testing

Genetic testing: For suspected primary HLH
Cytokine levels: IL-6, IL-18, IFN-γ (research/specialized centers)
18F-FDG PET/CT: May show characteristic patterns

Management Strategies

When to Start Immunosuppression: The Critical Decision

The decision to initiate immunosuppressive therapy in a critically ill patient with suspected cytokine storm syndrome requires careful consideration of risks and benefits.

Indications for Immediate Immunosuppression:

High probability of HLH/MAS (H-Score ≥169 or meeting HLH-2004 criteria)
Rapidly progressive multiorgan dysfunction despite supportive care
Characteristic laboratory profile (very high ferritin, cytopenias, elevated triglycerides)
Failure to respond to antimicrobials when infection suspected

Contraindications/Cautions:

Active, untreated infection (relative contraindication)
Suspected primary immunodeficiency without infectious workup
Uncertain diagnosis with alternative explanations

Hack - The "72-Hour Rule": In suspected cytokine storm syndromes, if there's no improvement or continued deterioration after 72 hours of optimal supportive care and antimicrobials (when indicated), strongly consider immunosuppressive therapy.

First-Line Therapies

Corticosteroids

Methylprednisolone: 1-2 mg/kg/day (maximum 1g/day for 3 days in severe cases)
Dexamethasone: 10 mg/m² every 12 hours (HLH-94 protocol)

Pearl: High-dose corticosteroids can provide rapid improvement in cytokine storm syndromes but may mask underlying infections.

IL-1 Inhibition

Anakinra: 100-400 mg daily (subcutaneous or intravenous)
Particularly effective in MAS and systemic JIA
Rapid onset of action (hours to days)

Hack: Anakinra can be used safely even in the presence of infection, making it an attractive option when diagnostic uncertainty exists.

IL-6 Inhibition

Tocilizumab: 8 mg/kg IV (maximum 800 mg) every 12-24 hours
Sarilumab: 400 mg IV single dose, may repeat
Particularly beneficial in COVID-19-associated cytokine storm

Second-Line and Salvage Therapies

Intravenous Immunoglobulin (IVIG)

Dose: 1-2 g/kg over 2-5 days
Mechanisms: Fc receptor blockade, complement inhibition

Etoposide

HLH-94 protocol: 150 mg/m² twice weekly
Reserved for confirmed HLH with poor response to first-line therapy
Requires careful monitoring for myelosuppression

Plasma Exchange/Hemofiltration

Consider in severe cases with multiorgan failure
May help remove circulating cytokines and inflammatory mediators

Novel Therapies

JAK inhibitors: Ruxolitinib, tofacitinib
Complement inhibition: Eculizumab
Anti-interferon therapies: Emapalumab (FDA-approved for refractory HLH)

Condition-Specific Considerations

COVID-19-Associated Cytokine Storm

Clinical Features:

Respiratory failure with bilateral infiltrates
Elevated D-dimer and thrombotic events
Less pronounced cytopenias compared to classic HLH
Elevated IL-6, ferritin, LDH

Management Pearls:

Dexamethasone: 6 mg daily for up to 10 days (proven mortality benefit)
Tocilizumab: Consider in patients with rapidly rising oxygen requirements
Baricitinib: JAK inhibitor with anti-inflammatory and antiviral properties

Hack: The "Rule of 6s" in severe COVID-19: IL-6 >40 pg/mL, ferritin >600 ng/mL, and LDH >600 U/L predict severe disease requiring intensive monitoring.

Macrophage Activation Syndrome in Rheumatic Diseases

Triggers:

Disease flares
Infections
Medication changes
Vaccination (rarely)

Management:

High-dose corticosteroids: First-line therapy
Anakinra: Highly effective, especially in systemic JIA
Cyclosporine: Alternative option (3-5 mg/kg/day)

Pearl: MAS can be the presenting feature of adult-onset Still's disease. Look for the characteristic evanescent rash and arthritis.

Infection-Associated HLH

Common Triggers:

EBV (most common)
CMV, HSV, VZV
Mycobacterial infections
Visceral leishmaniasis
Histoplasmosis

Management Strategy:

Treat underlying infection aggressively
Consider immunosuppression if severe HLH features present
Monitor closely for treatment response

Oyster: In EBV-HLH, rituximab may be beneficial by targeting EBV-infected B cells, but evidence is limited to case series.

Monitoring and Supportive Care

Laboratory Monitoring

Daily: CBC, ferritin, triglycerides, fibrinogen, LDH, liver function
Twice weekly: Soluble IL-2 receptor levels
Weekly: Bone marrow examination if hemophagocytosis initially absent

Supportive Care Measures

Infection prevention: Prophylactic antimicrobials during immunosuppression
Blood product support: Platelets <10×10⁹/L or active bleeding
Nutritional support: High metabolic demands
DVT prophylaxis: Increased thrombotic risk

Response Assessment

Clinical improvement: Fever resolution, improved organ function
Laboratory improvement: Rising cell counts, decreasing ferritin and triglycerides
Timing: Response typically seen within 48-72 hours of appropriate therapy

Hack: Serial ferritin levels are the best biomarker for monitoring treatment response. A failure of ferritin to decrease by 50% within one week suggests inadequate therapy or incorrect diagnosis.

Prognosis and Long-Term Management

Prognostic Factors

Poor Prognosis Indicators:

Age >60 years
CNS involvement
Delayed diagnosis (>4 weeks of symptoms)
Malignancy-associated HLH
Ferritin >50,000 ng/mL at presentation

Good Prognosis Indicators:

Young age
Infection-triggered HLH (if infection controlled)
Prompt recognition and treatment
MAS in known rheumatic disease

Outcomes

Overall mortality: 20-50% depending on subtype
Primary HLH: Often requires hematopoietic stem cell transplantation
Secondary HLH: May have better outcomes if trigger identified and treated

Special Populations

Pediatric Considerations

Higher likelihood of genetic causes
Different dosing regimens for medications
Consider genetic counseling for families

Pregnancy

Case reports of successful treatment with corticosteroids and IVIG
Avoid etoposide and other teratogenic agents
Multidisciplinary management essential

Immunocompromised Hosts

Higher risk of infection-triggered HLH
More challenging to distinguish from sepsis
May require modified immunosuppression protocols

Clinical Decision-Making Algorithms

Diagnostic Algorithm

Clinical suspicion: Fever + cytopenias + hepatosplenomegaly
Calculate H-Score: If ≥169, high probability of HLH
Essential laboratories: Ferritin, triglycerides, fibrinogen, sIL-2R
Bone marrow examination: If other criteria met
Genetic testing: If primary HLH suspected

Treatment Algorithm

Assess infection risk: Cultures, imaging, antimicrobials if indicated
Severity assessment: Organ dysfunction, laboratory abnormalities
First-line therapy: Corticosteroids ± IL-1/IL-6 inhibition
Monitor response: 48-72 hours
Escalate therapy: If inadequate response
Long-term management: Maintenance therapy if needed

Pearls and Pitfalls

Clinical Pearls

The "Ferritin >3,000" rule: Should trigger evaluation for cytokine storm syndromes
Bone marrow timing: Hemophagocytosis may develop during illness course
Treatment response: Should be evident within 72 hours of appropriate therapy
Infection screening: Always evaluate for EBV in suspected HLH
Family history: Important clue for primary HLH

Common Pitfalls

Delaying treatment: Waiting for complete diagnostic workup
Infection phobia: Avoiding immunosuppression in critically ill patients
Steroid dependence: Failing to add steroid-sparing agents
Monitoring gaps: Inadequate laboratory surveillance
Genetic testing: Forgetting to test family members in primary HLH

Practical Hacks

The "Anakinra trial": Safe to use even with infection concerns
Serial ferritin: Best biomarker for monitoring treatment response
The "72-hour rule": Consider immunosuppression if no improvement
Bone marrow repeat: If initially negative but suspicion remains high
Team approach: Early rheumatology consultation in suspected cases

Future Directions

Emerging Biomarkers

CXCL9: Promising biomarker for HLH diagnosis and monitoring
Neopterin: May help distinguish HLH from other inflammatory conditions
Cytokine panels: Comprehensive profiling for personalized therapy

Novel Therapeutics

Emapalumab: Anti-interferon-γ monoclonal antibody
JAK inhibitors: Targeting multiple inflammatory pathways
Complement inhibitors: For severe cases with hemolysis
Cell therapies: CAR-T cells for refractory cases

Personalized Medicine

Genetic profiling: To guide targeted therapies
Cytokine signatures: For treatment selection
Pharmacogenomics: Optimizing drug dosing and selection

Conclusions

Cytokine storm syndromes represent a critical intersection between rheumatology and critical care medicine. Early recognition, prompt diagnosis, and timely immunosuppressive therapy can be life-saving in these conditions. The key to successful management lies in maintaining a high index of suspicion, understanding the diagnostic criteria and their limitations, and being willing to initiate immunosuppression when indicated, even in the setting of diagnostic uncertainty.

Critical care physicians must become comfortable with the concept that inflammation, not infection, may be the primary driver of multiorgan dysfunction in these patients. The traditional approach of "treat the infection first" may need to be modified to a more nuanced understanding of when immunosuppression is indicated, even in the presence of infection.

As our understanding of these complex syndromes evolves and new targeted therapies become available, the prognosis for patients with cytokine storm syndromes continues to improve. However, early recognition and appropriate treatment remain the cornerstones of successful management.

References

Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119.
Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516.
Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811-1822.
Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome. Crit Care Med. 2016;44(2):275-281.
Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704.
Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72(2):326-334.
La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465-2477.

Saturday, August 23, 2025